Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 178

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates

Open access
Woodman, Scott E., Trent, Jonathan C., Stemke-Hale, Katherine, Lazar, Alexander J., Pricl, Sabrina, Pavan, Giovanni M., Fermeglia, Maurizio, Gopal, Y.N. Vashisht, Yang, Dan, Podoloff, Donald A., Ivan, Doina, Kim, Kevin B., Papadopoulos, Nicholas, Hwu, Patrick, Mills, Gordon B., Davies, Michael A. · 2009 · Molecular Cancer Therapeutics

Abstract

Point mutations in the KIT receptor tyrosine kinase gene have recently been identified in mucosal, acral lentiginous, and chronically sun-damaged melanomas. We have identified the first human melanoma cell line with an endogenous L576P mutation, the most common KIT mutation in melanoma (∼30-40%). In vitro testing showed that the cell viability of the L576P mutant cell line was not reduced by imatinib, nilotinib, or sorafenib small molecule KIT inhibitors effective in nonmelanoma cells with other KIT mutations. However, the viability of the mutant cells was reduced by dasatinib at concentrations as low as 10 nM (P = 0.004). Molecular modeling studies found that the L576P mutation induces structural changes in KIT that reduce the affinity for imatinib (ΔΔGbind = −2.52 kcal/mol) but not for dasatinib (ΔΔGbind = +0.32 kcal/mol). Two metastatic melanoma patients with the L576P KIT mutation were treated with dasatinib, including one patient previously treated with imatinib. Both patients had marked reduction (>50%) and elimination of tumor F18-fluorodeoxyglucose (FDG)-avidity by positron emission tomography (PET) imaging after dasatinib treatment. These data support the selective inhibitory effect of dasatinib against cells harboring the most common KIT mutation in melanoma, and thus has therapeutic implications for acrallentiginous, chronic sun-damaged, and mucosal melanomas. [Mol Cancer Ther 2009;8(8):2079–85]

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-09-0459

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 178

Metadata

Authors
Woodman, S. E., Trent, J. C., Stemke-Hale, K., Lazar, A. J., Pricl, S., Pavan, G. M., Fermeglia, M., Gopal, Y. N. V., Yang, D., Podoloff, D. A., Ivan, D., Kim, K. B., Papadopoulos, N., Hwu, P., Mills, G. B., & Davies, M. A.
Venue
Molecular Cancer Therapeutics
Published
2009-08-01
Volume
8
Issue
8
Pages
2079-2085
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2137020485
Cited by
178
References
2
FWCI
8.52
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates. https://app.cochat.ai/papers/10.1158/1535-7163.mct-09-0459
The paper
Woodman, S. E., Trent, J. C., Stemke-Hale, K., Lazar, A. J., Pricl, S., Pavan, G. M., Fermeglia, M., Gopal, Y. N. V., Yang, D., Podoloff, D. A., Ivan, D., Kim, K. B., Papadopoulos, N., Hwu, P., Mills, G. B., & Davies, M. A. (2009). Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-09-0459

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.